Activin Receptors, Type I
"Activin Receptors, Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the two types of ACTIVIN RECEPTORS or activin receptor-like kinases (ALK'S). There are several type I activin receptors. The major active ones are ALK-2 (ActR-IA) and ALK-4 (ActR-IB).
MeSH Number(s)
D08.811.913.696.620.682.700.062.500
D12.776.543.750.750.400.820.500.500
Below are MeSH descriptors whose meaning is more general than "Activin Receptors, Type I".
Below are MeSH descriptors whose meaning is more specific than "Activin Receptors, Type I".
This graph shows the total number of publications written about "Activin Receptors, Type I" by people in Harvard Catalyst Profiles by year, and whether "Activin Receptors, Type I" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 2 | 3 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 3 | 3 |
| 2004 | 1 | 3 | 4 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 4 | 4 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 2 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 2 | 3 |
| 2016 | 3 | 3 | 6 |
| 2017 | 3 | 6 | 9 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 0 | 3 |
| 2020 | 2 | 1 | 3 |
| 2021 | 2 | 2 | 4 |
Below are the most recent publications written about "Activin Receptors, Type I" by people in Profiles.
-
Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617G > A in the ACVR1 gene. Stem Cell Res. 2021 07; 54:102424.
-
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight. 2021 04 22; 6(8).
-
ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders. J Clin Invest. 2021 02 15; 131(4).
-
Suppressed prefrontal cortex oscillations associate with clinical pain in fibrodysplasia ossificans progressiva. Orphanet J Rare Dis. 2021 01 30; 16(1):54.
-
Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma. J Med Chem. 2020 09 10; 63(17):10061-10085.
-
Activin A does not drive post-traumatic heterotopic ossification. Bone. 2020 09; 138:115473.
-
Inhibition of bone morphogenetic protein 6 receptors ameliorates Sjögren's syndrome in mice. Sci Rep. 2020 02 19; 10(1):2967.
-
Tyrosine kinase Eph receptor A6 sensitizes glioma-initiating cells towards bone morphogenetic protein-induced apoptosis. Cancer Sci. 2019 Nov; 110(11):3486-3496.
-
A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling. Sci Adv. 2019 08; 5(8):eaav6789.
-
Integrative Genomics Analysis Identifies ACVR1B as a Candidate Causal Gene of Emphysema Distribution. Am J Respir Cell Mol Biol. 2019 04; 60(4):388-398.